REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

This trial investigates a new type of immunotherapy called CAR T-cell therapy that targets two proteins, CD19 and CD22, found on B-cell leukemia cells. The therapy is given along with chemotherapy to children and young adults whose leukemia has come back or has not responded to s…

This Phase 1 trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. Patients' own immune cells are collected, genetically modified to recognize and attack cancer cells, and then infused back af…

This study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …

This study tests a new oral drug (revumenib) combined with standard chemotherapy for infants and young children with a specific type of leukemia (KMT2A-rearranged) that has returned or not responded to treatment. The goal is to see if the combination is safe and works better than…

This early-phase study tests a drug called palbociclib, given alone or with other medicines, in people whose leukemia has returned or stopped responding to standard treatments. The main goal is to find the safest dose and understand side effects. About 32 adults with acute myeloi…

This study tests a new way to treat adults with a specific type of leukemia (Ph+ ALL) that has come back or not responded to treatment. The approach combines low-intensity chemotherapy with two targeted drugs, ponatinib and blinatumomab, to kill cancer cells and boost the immune …

This early-stage study tests a new cell therapy for adults with a hard-to-treat type of leukemia (ALL). Doctors take a patient's own white blood cells, add a special gene to help them find and kill cancer cells, and give them back after chemotherapy. The main goals are to check s…

This early-stage trial tests a new approach for adults with acute lymphoblastic leukemia that has not responded to chemotherapy. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack cancer cells with CD22 and CD19 proteins, and infuse them…

This trial is testing whether adding two targeted drugs, venetoclax and navitoclax, to standard chemotherapy can help children and young adults with acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. The study has two phases: first, finding the b…